Ironwood Pharmaceuticals Revenue Quarterly YoY Growth:
-73.42% for March 31, 2013Ironwood Pharmaceuticals Historical Revenue Quarterly YoY Growth Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| March 31, 2013 | -73.42% |
| Dec. 31, 2012 | -16.09% |
| Sept. 30, 2012 | 689.1% |
| June 30, 2012 | 29.68% |
| March 31, 2012 | 19.64% |
| Dec. 31, 2011 | 91.71% |
| Sept. 30, 2011 | 34.87% |
| June 30, 2011 | 22.57% |
| March 31, 2011 | 15.83% |
| Dec. 31, 2010 | 99.57% |
| Sept. 30, 2010 | -40.62% |
| June 30, 2010 | 39.00% |
| March 31, 2010 | 68.95% |
| Dec. 31, 2009 | 68.96% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
IRWD Revenue Quarterly YoY Growth Benchmarks
| Companies | |
|---|---|
| Forest Laboratories | -22.17% |
| Valeant Pharmaceuticals International | 24.79% |
| Synergy Pharmaceuticals |
IRWD Revenue Quarterly YoY Growth Rankings
| Overall |
39th percentile 4818 of 8002 |
| Sector |
28th percentile 491 of 684 in Healthcare |
| Industry |
18th percentile 53 of 65 in Diagnostics & Research |
IRWD Revenue Quarterly YoY Growth Range, Past 5 Years
| Minimum | -73.42% | Mar 2013 |
| Maximum | 689.1% | Sep 2012 |
| Average | 74.98% |
IRWD News
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013
Business Wire May 14
Business Wire May 14
